

MOLECULAR FRACTIONATION WITH CONJUGATE CAPS STUDY OF THE INTERACTION OF THE ANACARDIC ACID WITH THE ACTIVE SITE OF *TRYPANOSOMA CRUZI* GAPDH ENZYME: A QUANTUM INVESTIGATION

MÁRCIA MACHADO MARINHO^{1*}, RICARDO PIRES DOS SANTOS², EVELINE MATIAS BEZERRA³,
RONER FERREIRA COSTA³, CIRO SIQUEIRA FIGUEIRA², ALICE MARIA COSTA MARTINS¹, PEDRO LIMA NETO⁴,
EMMANUEL SILVA MARINHO⁵, VALDER NOGUEIRA FREIRE⁶, EUDENILSON LINS ALBUQUERQUE⁷

¹Department of Clinical and Toxicological Analysis, Federal University of Ceara, Ceara, Brazil. ²Department of Computer Engineering/Biotechnology, Federal University of Ceara, Ceara, Brazil. ³Department of Exact and Natural Sciences, Federal Rural University of Semiárid (UFERSA), Mossoró, Rio Grande do Norte, Brazil. ⁴Department of Analytical Chemistry and Physical-Chemistry, Federal University of Ceara, Ceara, Brazil. ⁵Dom Aureliano Matos Faculty of Philosophy, Ceara State University, Ceara, Brazil. ⁶Department of Physics, Federal University of Ceara, Ceara, Brazil. ⁷Department of Biophysics and Pharmacology, Federal University of Rio Grande do Norte, Rio Grande do Norte, Brazil. Email: marinho.marcia@gmail.com

Received: 27 September 2019, Revised and Accepted: 09 November 2019

ABSTRACT

Objective: The objective of this study was to use the molecular fractionation with conjugate caps (MFCC) method to elucidate the possible interaction mechanism of anacardic acid (AA) with the saturated alkyl chain (AA0) in the *Trypanosoma cruzi* glyceraldehyde-3-phosphate dehydrogenase (TcGAPDH) enzyme.

Methods: Initially, the geometry optimization of the AA three-dimensional structure (with the pentadecyl chain) was performed using density functional theory (B3LYP) calculations. With the AA0 optimization data, it was possible to plot the molecular electrostatic potential (MESP) surface. Molecular docking simulation was performed using automated coupling with the AutoDock Vina program. The best-fit conformation in the docking simulation of AA0 is the binding site used for the construction of the TcGAPDH-AA0 complex. Interaction energies between the AA0 molecule and the amino acid residues of the TcGAPDH enzyme were estimated using the MFCC strategy.

Results: To obtain more reliable quantitative information on the interaction of AA with the active site of the TcGAPDH enzyme, the fragmentation method was combined with conjugated layers (MFCC) and molecular docking. It can be observed that the AA0 molecule occupies a region near the active site of the cholepin molecule in the TcGAPDH enzyme, and the Ile13 residue has the strongest binding energy of approximately 25 kcal/mol with AA0, through a strong Van der Waals interaction.

Conclusion: The paper presents an improved quantitative analysis approach for assessing the contribution of individual amino acids to the free energy of interaction between AA and TcGAPDH. Specifically, the paper illustrates the advantageous approach of combining molecular docking with the MFCC method.

Keywords: Anacardic acid, Chagas disease, Density functional theory, Glyceraldehyde-3-phosphate dehydrogenase, *Trypanosoma cruzi*, Molecular electrostatic potential, Molecular fractionation with conjugate caps, molecular docking.

© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>) DOI: <http://dx.doi.org/10.22159/ajpcr.2019.v12i12.36193>

INTRODUCTION

Caused by the parasite protozoan hemoflagellate *Trypanosoma cruzi* (TC), Chagas disease is commonly transmitted to humans by the insect vector *Triatoma infestans* [1]. This is an endemic disease in tropical and subtropical regions of Latin America, Africa, and Asia, affecting millions of people each year [2]. Through immigration, the disease has also affected non-endemic regions, such as the United States [3,4]. Benznidazole and nifurtimox, the drugs used to treat Chagas disease, are not effective against certain forms of the disease, in addition to having significant side effects [5,6]. Therefore, it is important to develop new drugs so these problems can be minimized or eliminated.

The mechanism of action of trypanocidal drugs is generally not well elucidate. Many published studies assume that the drug produces free radicals to which TC is particularly sensitive [7], but some of the proposed mechanisms of action have been challenged [8]. The inhibition of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) from TC (TC glyceraldehyde-3-phosphate dehydrogenase [TcGAPDH]), on the other hand, was also proposed as an explanation for the trypanocidal effect

of drugs [9-11]. This enzyme is responsible, in the glycolytic pathway of the parasite, for the conversion of glyceraldehyde-3-phosphate into 1,3-bisphosphoglycerate in the presence of nicotinamide-adenine-dinucleotide (NAD)⁺ inorganic phosphate [12,13]. Through anaerobic glycolysis in the cytoplasm, its inhibition can modify the energetic metabolism and the production of adenosine triphosphate, important for the parasite's life cycle [14,15]. In addition to its primordial role in glycolysis in the cytoplasm, GAPDH has also been associated with several non-metabolic events, such as the onset of apoptosis, axoplasmic transport, activation of transcription, and transport of ER to Golgi [16,17]. Thus, this enzyme can be an important target for the rational planning of new drugs.

Various substances extracted from medicinal plants have been tested for TcGAPDH inhibition [18-20]. For instance, cholepin, a furanocoumarin isolated from species of the *Rutaceae* family, showed a high inhibitory effect on TcGAPDH [21,22]. Another important natural product inhibitor of TcGAPDH is the 2-hydroxy-6-pentadecyl-benzoic acid, also known as anacardic acid (AA) [23]. It is found in the shells of cashew nuts, the *Anacardium occidentale*, a plant native to the Northeastern

Brazilian coast, and also found in Central America and countries such as India, Asia, and Africa [24]. Several biological activities of AA have been reported: Antimicrobial, antifungal, antioxidant, antitumoral, antiparasitic, molluscicidal, larvicidal, and insecticidal [25-29]. The AA is a phenolic lipid, having the structure of a salicylic acid substituted by an alkyl chain with 15 carbons. The alkyl chain may be saturated or unsaturated (monoene, diene, or triene) [30]. All forms of AA (saturated or unsaturated alkyl chain) show an inhibitory effect on TcGAPDH; however, the form with the saturated alkyl chain shows the greatest effects [31]. Because of its high inhibition capacity, the AA has been studied as a promising trypanocidal drug with IC_{50} of 28 μ M [23]. TcGAPDH has not yet been cocrystallized with AA, and details of its mechanism of interaction with the enzyme site of action are not well elucidated.

Computational chemistry has been widely used for the planning of biologically active compounds and the understanding of their mechanisms of action [32,33]. Density functional theory (DFT) is a quantum computational method that allows the determination (with acceptable accuracy) of various drug properties, such as geometric configurations of the lowest energy, expected positions of the constituent atoms, electronic charge distributions, and vibrational frequencies [34,35]. Changes in the geometric configuration and charge distribution of a drug molecule caused by its interaction with the active site of an enzyme play a key role in its biological activity [36,37]. Molecular docking is a computational method usually based on force fields of classical molecular mechanics that predict the mode of binding of a small-molecule ligand to the active site of a macromolecular ligand to form a stable complex [38], this method is used in the search for new ligands for drug therapy because of their low computational cost when compared to methods based on quantum mechanics [39]. However, the typically used docking methods do not correctly predict the binding energy of a ligand-receptor complex [40,41]; moreover, the molecular fractionation with conjugate caps (MFCC) is a more powerful approach using quantum mechanics calculations to determine interaction energies for protein-ligand systems [42,43]. In this method, the interaction energy is calculated by summing the interactions between the individually capped protein fragments (individual amino acid-based fragments) and the ligands [44]. The MFCC combined with the docking approach can provide more reliable quantitative information on the interaction of drugs with the active site of macromolecular targets.

Devipriya and Kumarad have [45] performed molecular docking and the DFT approach to show changes in the conformation and charge density of AA molecules before and after interaction with the active site of the p300 enzyme. Da Silva *et al.* [46] and Freitas *et al.* [31] studied the interaction of AA and analogs with TcGAPDH through molecular docking and biochemical assays. However, a more detailed analysis of this interaction (using the MFCC method) together with conformational and charge density changes of the ligand molecule (before and after docking) have not been conducted. To better elucidate the possible interaction mechanism of AA with the saturated alkyl chain (AA0) in the TcGAPDH enzyme, molecular docking and MFCC analyzes of the AA0 molecule were performed at the active site of the enzyme. Results were compared with the binding energy (calculated by MFCC) of NAD⁺ cofactor crystalized with TcGAPDH. From this perspective, the present work aims using the MFCC quantum method to measure the interaction of AA (with the saturated alkyl chain) and the TcGAPDH enzyme, identifying the component residues of their binding sites, as well as assessing the peculiarities surrounding the drug-receptor complexes, thus elucidating the interaction mechanism.

METHODS

Geometry optimization and molecular electrostatic potential (MESP) surface

Initially, the geometry optimization of the AA three-dimensional (3D) structure (with the pentadecyl chain) obtained from the ZINC database (ZINC code: 8234355) [47] was performed using DFT

(B3LYP) calculations. The Gaussian 03 program (Gaussian, Inc.) was used, adopting the B3LYP hybrid functional exchange-correlation and the 6-311+G (d, p) basis set to expand the electronic states. Structural convergence of isolated neutral AA0 (gas phase) was reached when the following thresholds were met: Maximum force per atom $<1.5 \times 10^{-5}$ Ha \AA^{-1} and RMS force $<1.0 \times 10^{-5}$ Ha \AA^{-1} , self-consistent field energy variation $<10^{-7}$ Ha, and maximum atomic displacement $<6 \times 10^{-5}$ \AA . The lowest energy configuration (optimized) was represented as AA0. With the AA0 optimization data, it was possible to plot the MESP surface.

Molecular docking

Molecular docking simulation was performed using automated coupling with the AutoDock Vina program (Molecular Graphics Lab) [48]. The crystallographic structure of TcGAPDH complexed with cholepin (TcGAPDH-cholepin) was obtained from RCSB protein data bank (PDB) (code: 1K3T) [49]. The ligand used was the optimized AA0, and the receptor was the chain C of the TcGAPDH enzyme after the removal of the cholepin of the complex. A box region with 820 nm³ centered on and encompassing the active site was defined as the receptor search volume. The best-fit conformation in the docking simulation of AA0 is the binding site used for the construction of the TcGAPDH-AA0 complex. To compare the position of the ligand at the binding site, the Chain A of the TcGAPDH-NAD⁺ cofactor (PDB code: 1QXS) complexes were used [10]. Molecular graphics and docking were displayed using the UCSF Chimera 1.8 package [50] and Discovery Studio Visualizer.

MFCC

To estimate the total energy of interaction, all 359 amino acid residues of the C chain of the enzyme of the TcGAPDH-AA0 complex were taken into account, seeking to disregard not important interactions. For each amino acid residue, sets of four amino acids were used as caps, two on each side, to increase accuracy when measuring the interaction energy. Interaction energies between the AA0 molecule and the amino acid residues of the TcGAPDH enzyme were estimated using the MFCC strategy [36,45]. The binding energy between the inhibitor molecule AA0 and the amino acid residue R_i is given by $E(\text{AA}-R_i)$:

$$E(\text{AA}-R^i) = E(\text{AA}-C^{i-1}R^iC^{i+1}) - E(C^{i-1}R^iC^{i+1}) - E(\text{AA}-C^{i-1}C^{i+1}) + E(C^{i-1}C^{i+1})$$

where the C^i (cap) is obtained by attaching a carboxyl or amine group to the dangling bond of the residue R^i . On the right side of the equation, $E(\text{AA}-C^{i-1}R^iC^{i+1})$, is the total energy of the system formed by the AA molecule and the capped residue; the $E(C^{i-1}R^iC^{i+1})$ term is the total energy of the blocked residue alone; and $E(\text{AA}-C^{i-1}C^{i+1})$ is the total energy of the system formed by the AA and the covers alone. To conclude, $E(C^{i-1}C^{i+1})$ is the total energy of the system formed only by the molecular caps. For the first-principles calculations, the methodology seen in early works [44,51], the positions of the non-hydrogen atoms were kept fixed while the positions of the hydrogen atom and AA0 were in principle optimized using the CHARMM force field [52], which has parameters specific for amino acids. Simulations were performed within the formalism of the DFT, using local density approximation for the correlation-change functional with a dispersion correction scheme (DFT/LDA/OBS) was carried out using the Dmol3 code [53,54]. To expand the Kohn-Sham electron orbitals, a set of numerical bases and double polarization (dynamic nuclear polarization [DNP]) was selected, considering all electrons, explicitly, and with restricted spin. The DNP basis set has an accuracy equivalent to the 6-311+G (3df, 2pd) Gaussian basis set [53,55], with negligible basis set superposition error. The orbital cutoff radius for this basis set was set to 3.7 \AA and the self-consistent field convergence threshold to 10^{-6} Ha. The binding energy of chain A of TcGAPDH-NAD⁺ cofactor complexes was also calculated (by MFCC) to be compared with the TcGAPDH-AA0 complex.

RESULTS AND DISCUSSION

The MESP surface

The MESP surface allows to visualize the relative polarity of the compounds [56] and allows to predict the binding site between biological

molecules and their receptors [57,58], as well as being an important tool in the study of new drugs [59,60]. Associated with the dipole moment, the electronegativity and partial charge of the MESP [61], can be used to predict the types of intermolecular interaction, the molecule may carry as well as the sites of these interactions.

Given the electrostatic potential energy between a hypothetically positively charged ion (+1) located at a point (x, y, and z) and the molecule, the electrostatic potential at x, y, and z is calculated. The ion repulsion means the potential is positive, being the ion attracted by the molecule, then the potential is negative. Thus, electron-poor regions usually have positive potentials and electron-rich regions usually have negative potentials, the MEP at a point r in the space around a molecule (in atomic units) can be expressed as follows [62]:

$$V(r) = \sum_A \frac{Z_A}{|R_A - r|} - \int \frac{\tilde{n}(r')}{|r - r'|} dr'$$

where Z_A is the charge on nucleus A, located at R_A and $\rho(r')$ is the electronic density function for the molecule. $V(r)$ is the resulting electrostatic net effect produced at the point r by both the electrons and the cores of the molecule, where the first term represents the contributions due to the potential for electrons and the second term due to the cores. The knowledge of the charge distribution, identifying their partial densities, helps in understanding the form of interaction between a molecule and another, and thus, one can identify the molecular reactive site [63,64].

AA (15:0) has in its structure a nucleus derived from salicylic acid substituted with an alkyl chain composed of 15 carbon atoms, linked




Fig. 1: Two-dimensional molecular structure of saturated alkyl anacardic acid 0

only by typo sigma bonds (Fig. 1), the electrostatic potential map is shown in Fig. 2, the 3D charge distributions of the molecule, while negative electrostatic potentials (with intensity proportional to the absolute value of the potential energy) are shown in red, positive electrostatic potentials are visualized in blue and green, areas with potentials close to zero are perceived.

A negative charge partial density in the carboxyl group indicates a region rich in electrons, this fact can be explained by the presence of pairs of non-binding electrons in oxygen, and by the difference of electronegativity in relation to the carbon atom, being indicative of nucleophilic site. While in the alkyl group, a potential close to zero was observed, characterizing a region predominantly not polar.

Molecular docking and MFCC

The best-fit conformation in the docking simulation of (AA0) is shown in Fig. 3, together with the cholepin docking configuration (obtained from crystallographic data of the TcGAPDH complex - cholepin, PDB 1K3T) for comparison. It is possible to observe that the AA0 molecule occupies a region near the active site of the cholepin molecule in the TcGAPDH enzyme. The AA0 can interact with a large number of residues due to its long chain. In addition, it consists of a polar head with a benzene ring and a long hydrophobic tail. The polar head favors the formation of hydrogen bonds, while the tail can interact with amino acids that have a hydrophobic character.

Fig. 4 shows the molecular two-dimensional interaction map for AA0 and TcGAPDH complex. As it can be seen, there are many kinds of interaction, since weak interactions by London dispersion forces (pale pink), sigma-pi interactions (lilac), pi-pi stacking (darker pink), and hydrogen bonding (bright green) are found. Those interactions are in agreement with AA0/cholepin docking with TcGAPDH complex. The TcGAPDH-AA0 complex (with the AA0 better conformation in the docking simulation) was used in the MFCC calculations.

Based on the DFT, the interaction energy of the amino acid residues was determined, through computations using the MFCC approach. The amino acids that showed significant interaction energy for stabilizing the AA0 molecule were: Ile13; Met16; Ser134,224; Ala135,164,228; Pro136; Cys165; Thr167,197,226; His194; Gly227; Arg249; Asp334; Asn335; Glu336; and Tyr339. The binding site, interaction energy, and residues domain (BIRD) panel (Fig. 5) show a graphical display with interaction energies between ligand and the most important amino acid residues comprising the binding site of the TcGAPDH enzyme. This panel shows relevant residues interacting with AA contributing to its energy stabilization at the binding site of the gGAPDH enzyme.




Fig. 2: Molecular electrostatic potential surface of saturated alkyl anacardic acid 0




Fig. 3: *Trypanosoma cruzi* glyceraldehyde-3-phosphate dehydrogenase (TcGAPDH) complexes crystallized with (a) nicotinamide-adenine-dinucleotide, (b) chalepin. Docking between TcGAPDH and anacardic acid (AAO) (c) and binding site of AAO and chalepin in the TcGAPDH (d)




Fig. 4: Two-dimensional molecular map for intermolecular interactions between anacardic acid 0 and *Trypanosoma cruzi* glyceraldehyde-3-phosphate dehydrogenase residues

This panel is a new version of BIRD [43] and shows: (i) The interaction energy of each residue with the AA0 molecule using horizontal bars, based on which can quantitatively estimate the role of each residue in the binding site, i.e., its efficacy to attract or repel the drug; (ii) the most significant residues for the bond on the left side; (iii) the atoms that show the shortest distance between the amino acid residue and the ligand; (iv) the left side panel containing the minimum distance in angstroms between amino acid ligands; and (v) the bars indicating the interaction strength between ligand and residues of TcGAPDH show colors that depend on the side chain of each amino acid score.

It is possible to see in Fig. 5 the attached BIRD that 22 residues contribute to the stabilization of AA0: Arg12, Ile13, Arg15, Met16, Asp38, Glu109, Pro136, Ala164, Ser165, Cys166, Thr167, His194, Thr197, Thr226, Ala228, Arg249, Asp254, Asp334, Asn335, Glu336, Tyr339, and Arg342, whereas only one Ala135 amino acid residue has positive (repulsive) interaction energy. Pavão *et al.* [49] reported that the residues Thr167, Cys166, Arg249, and Asp210 of the gGAPDH enzyme have important interactions with chalepin. The residue Thr167 interacts with the oxygen of the CO group of chalepin through the W739 [49]. The Cys166 residue shows a characteristic hydrophobic interaction with the 1,1-dimethylallyl group; a hydrogen interaction with the Arg249 is also reported, and finally, a weak interaction of hydrogen with Asp210 is intermediated by W812 water. Due to the structural differences of the ligands, the above amino acids may or may not show molecular interactions relevant to AA0 stabilization, as it can be observed in the BIRD panel.

Residue Ile13 has the strongest binding energy, approximately 25 kcal/mol with AA0, through a strong Van der Waals interaction involving the AA0 tail and the side chain of Ile13, both with hydrophobic characteristics. Although the hydrophobic interactions are admittedly one of the weakest, it is relatively strong because of the proximity




Fig. 5: (a) Anacardic acid (AA) binding site obtained from molecular docking, highlighting important residues of *Trypanosoma cruzi* glyceraldehyde-3-phosphate dehydrogenase (TcGAPDH): Tyr339, Ser165, Cys166, Thr167, Ile13, Thr226, and Glu336. (b) Another view of the AA binding site obtained from molecular docking, highlighting Pro136, Ala 135, Thr197, and Met16 residues. (c) Interaction energy, binding site, and domain of residues, showing relevant residues interacting with AA, contributing to its energy stabilization at the binding site of the TcGAPDH enzyme. Amino acid residues have colors that depend on the side chain of each: Nonpolar, aliphatic; aromatic; polar, uncharged; sulfur-containing; charged negative (acidic); and charged positive (basic)

between the chemical groups of both binder and residue, which is about 2 Å, as well as the extent of the side chain of the Ile13 residue, which is approximately 4 Å.

The second amino acid with the strongest interaction energy is Glu336, with a binding energy around 15.0 kcal/mol, due to the natural formation of an AA0 electrostatic dipole inside the tail-binding site, with absence of electrons, which favors the interaction with amino acids that have more electronegative atoms or side chains, which is the case of Glu336 that has the COO⁻ group.

The third most important residue, Tyr339, has binding energy with the AA0 of 14.1 kcal/mol due to a sigma-pi interaction, caused by the presence of an aromatic ring rich in electrons in the side chain of that amino acid, as well as positive characteristic of the AA0 tail. We can also observe that the method used to calculate the interaction energy was able to describe a pi-pi interaction between the aromatic rings of AA0 and the side chain of the His194 residue, with an intensity of about 5.0 kcal/mol. The residues Thr167 and Thr226 interact with AA0 through a hydrogen interaction of about 12.0 kcal/mol and 13.0 kcal/mol, respectively. The hydrogen of the OH group of Thr167 interacts with the oxygen of the CO group of the polar region of AA0, which are separated by a distance of 1.95 Å, whereas the other hydrogen bond is due to the interaction of the hydroxyl hydrogen of the residue Thr226 and the oxygen of the AA0 hydroxyl group. Together, Ser165 and Cys166 create a region with a positive electrostatic potential, which couples with the region of the AA0 hydrophobic tail that has electronegative characteristics, thus producing a relevant attractive interaction between these amino acids of approximately 13.0 kcal/mol.

CONCLUSION

The paper presents an improved quantitative analysis approach for assessing the contribution of individual amino acids to the free energy of interaction between organic ligands (such as AA) and target protein (like GAPDH). Specifically, the paper illustrates the advantageous

approach of combining the molecular docking (such as the mostly used AutoDock Vina program) with the MFCC method. It was obtained more reliable quantitative information on the interaction of AA with the active site of the enzyme TcGAPDH by combining MFCC with molecular docking. It has been verified that the AA0 molecule occupies a region near the active site of the chalepin molecule in the TcGAPDH enzyme and that residue Ile13 has the strongest binding energy, approximately 25 kcal/mol with AA0, through a strong Van der Waals interaction.

ACKNOWLEDGMENTS

Acknowledge the financial support received during the development of this work from the Brazilian National Council (CNPq).

AUTHORS' CONTRIBUTIONS

The research was developed with: Conceptualization and use of the software by (Prof. Dr. Ricardo Santos and Prof. Dr. Valder Nogueira); Methodology (Msc. Marcia Marinho, Prof. Dr. Ricardo Santos, Dr^a Eveline Bezerra, Prof. Dr. Roner Costa and Prof. Dr. Emmanuel Marinho); Investigations and resources (Prof. Dr. Ricardo Santos and Msc. Marcia Marinho); Supervision and Project administration (Prof. Dr. Ricardo Santos and Prof. Dr. Eudenilson Albuquerque); Funding Acquisition (Prof. Dr. Ricardo Santos, Prof. Dr. Valder Nogueira, Prof^a Dr^a Alice Martins, prof. Dr. Pedro Lima Neto and Prof. Dr. Eudenilson Albuquerque); and Writing-Original Draft Preparation (Msc. Marcia Marinho, Dr^a Eveline Bezerra, Msc. Ciro Figueira, Prof. Dr. Roner Costa and prof. Dr. Emmanuel Marinho). All authors had a contribution to the final manuscript.

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

FUNDING

This research received financial support from Brazilian National Council (CNPq) projects 151182/2013-2 and 447592/2014-9. This

study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – Brasil (CAPES) – Finance Code 001.

REFERENCES

- Rassi A, Rassi A, Marin-Neto JA. Chagas disease. Lancet 2010;375:1388-402. Available from: <http://www.sciencedirect.com/science/article/pii/S014067361060061X>.
- Schmunis GA. Epidemiology of Chagas disease in non-endemic countries: The role of international migration. Mem Inst Oswaldo Cruz 2007;102:75-85.
- Bern C, Kjos S, Yabsley MJ, Montgomery SP. *Trypanosoma cruzi* and Chagas' disease in the united states. Clin Microbiol Rev 2011;24:655-81.
- Jackson Y, Gétaz L, Wolff H, Holst M, Mauris A, Tardin A, et al. Prevalence, clinical staging and risk for blood-borne transmission of Chagas disease among latin American migrants in Geneva, Switzerland. PLoS Negl Trop Dis 2010;4:1-7.
- Coura JR, de Castro SL. A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz 2002;97:3-24.
- Nagajyothi F, Machado FS, Burleigh BA, Jelicks LA, Scherer E, Mukherjee S, et al. Mechanisms of *Trypanosoma cruzi* persistence in Chagas disease. Cell Microbiol 2013;14:634-43.
- Morillo CA, Marin-Neto JA, Avezum A, Sosa-Estani S, Rassi A, Rosas F, et al. Randomized Trial of benznidazole for chronic Chagas' cardiomyopathy. N Engl J Med 2015;373:1295-306.
- Sosa-Estani S, Viotti R, Leonor ES. Therapy, diagnosis and prognosis of chronic Chagas disease: Insight gained in Argentina. Mem Inst Oswaldo Cruz 2009;104:167.
- Bakker BM, Westerhoff HV, Opperdoes FR, Michels PA. Metabolic control analysis of glycolysis in trypanosomes as an approach to improve selectivity and effectiveness of drugs. Mol Biochem Parasitol 2000;106:1-10.
- Ladame S, Castilho MS, Silva CH, Denier C, Hannaert V, Périé J, et al. Crystal structure of *Trypanosoma cruzi* glyceraldehyde-3-phosphate dehydrogenase complexed with an analogue of 1,3-bisphospho-D-glyceric acid: Selective inhibition by structure-based design. Eur J Biochem 2003;270:4574-86.
- Prokopczyk IM, Ribeiro JF, Sartori GR, Sesti-Costa R, Silva JS, Freitas RF, et al. Integration of methods in cheminformatics and biocalorimetry for the design of trypanosomatid enzyme inhibitors. Future Med Chem 2013;6:17-33.
- Harris JL, Waters M. In: Boyer P, editor. The Enzymes. 3rd ed. New York: Academic Press; 1976. p. 1-49.
- Zinsser VL, Hoey EM, Trudgett A, Timson DJ. Biochemical characterisation of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) from the liver fluke, *Fasciola hepatica*. Biochim Biophys Acta 2014;1844:744-9.
- Nowicki MW, Tulloch LB, Worrall L, McNae IW, Hannaert V, Michels PA, et al. Design, synthesis and trypanocidal activity of lead compounds based on inhibitors of parasite glycolysis. Bioorg Med Chem 2008;16:5050-61.
- Yang S, Pannecouque C, Daelemans D, Ma XD, Liu Y, Chen FE, et al. Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors. Eur J Med Chem 2013;65:134-43.
- Nicholls C, Li H, Liu JP. GAPDH: A common enzyme with uncommon functions. Clin Exp Pharmacol Physiol 2012;39:674-9.
- Tarze A, Deniaud A, Le Bras M, Maillier E, Molle D, Laroche N, et al. GAPDH, a novel regulator of the pro-apoptotic mitochondrial membrane permeabilization. Oncogene 2007;26:2606-20.
- Menezes IR, Lopes JC, Montanari CA, Oliva G, Pavão F, Castilho MS, et al. 3D QSAR studies on binding affinities of coumarin natural products for glycosomal GAPDH of *Trypanosoma cruzi*. J Comput Aided Mol Des 2003;17:277-90.
- Hanau S, Rinaldi E, Dallochio F, Gilbert IH, Dardonville C, Adams MJ, et al. 6-phosphogluconate dehydrogenase: A target for drugs in African trypanosomes. Curr Med Chem 2004;11:2639-50.
- De Marchi AA, Castilho MS, Nascimento PG, Archanjo FC, Del Ponte G, Oliva G, et al. New 3-piperonylcoumarins as inhibitors of glycosomal glyceraldehyde-3-phosphate dehydrogenase (gGAPDH) from *Trypanosoma cruzi*. Bioorg Med Chem 2004;12:4823-33.
- Schmelzer GH, Gurib-Fakim R, Ameenah B. Plant Resources of Tropical Africa 11(1): Medicinal Plants 1. Vol. 11. Wageningen: PROTA Foundation; 2008.
- Vieira PC, Mafezoli J, Pupo MT, Fernandes JB, da Silva MF, de Albuquerque S, et al. Strategies for the isolation and identification of trypanocidal compounds from the rutales. Pure Appl Chem 2001;73:617-22.
- Pereira JM, Severino RP, Vieira PC, Fernandes JB, da Silva MF, Zottis A, et al. Anacardic acid derivatives as inhibitors of glyceraldehyde-3-phosphate dehydrogenase from *Trypanosoma cruzi*. Bioorg Med Chem 2008;16:8889-95.
- Santos RP, Santiago AA, Gadelha CA, Cajazeiras JB, Cavada BS, Martins JL, et al. Production and characterization of the cashew (*Anacardium occidentale* L.) peduncle bagasse ashes. J Food Eng 2007;79:1432-7.
- Hemshekhkar M, Santhosh MS, Kemparaju K, Girish KS. Emerging roles of anacardic acid and its derivatives: A pharmacological overview. Basic Clin Pharmacol Toxicol 2012;110:122-32.
- Kubo I, Masuoka N, Ha TJ, Tsujimoto K. Antioxidant activity of anacardic acids. Food Chem 2006;99:555-62.
- Mendes N, Oliveira A. Atividade moluscicida da mistura de ácidos 6-n-alquil salicílicos (ácido anacárdico) e dos seus complexos com cobre (II) e chumbo (II). Rev Soc Bras Med 1990;23:217-24. Available from: <http://www.scielo.br/pdf/rsbmt/v23n4/07.pdf>.
- Oliveira MS, Morais SM, Magalhães DV, Batista WP, Vieira ÍG, Craveiro AA, et al. Antioxidant, larvicidal and antiacetylcholinesterase activities of cashew nut shell liquid constituents. Acta Trop 2011;117:165-70.
- Tan J, Chen B, He L, Tang Y, Jiang Z, Yin G, et al. Anacardic acid (6-pentadecylsalicylic acid) induces apoptosis of prostate cancer cells through inhibition of androgen receptor and activation of p53 signaling. Chin J Cancer Res 2012;24:275-83.
- Tyman JH. Long-chain phenols. Part III identification of the components of a novel phenolic fraction in *Anacardium occidentale* (cashew nut-shell liquid) and synthesis of the saturated member. J Chem Soc Perkin 1973;1:1639-47.
- Freitas RF, Prokopczyk IM, Zottis A, Oliva G, Andricopulo AD, Trevisan MT, et al. Discovery of novel *Trypanosoma cruzi* glyceraldehyde-3-phosphate dehydrogenase inhibitors. Bioorganic Med Chem 2009;17:2476-82.
- Dahl SG, Sylte I. Molecular modelling of drug targets: The past, the present and the future. Basic Clin Pharmacol Toxicol 2005;96:151-5.
- Roberto CA, Marinho ES, Campos OS. Neo-chlorogenic acid: Conformational and molecular analysis by semi-empirical methods. Int J Recent Res Rev 2019;12:21-6.
- Ziegler T, Autschbach J. Theoretical methods of potential use for studies of inorganic reaction mechanisms. Chem Rev 2005;105:2695-722.
- Bezerra EM, Flores MZ, Caetano EW, Freire VN, Lemos V, Cavada BS, et al. Quantum mechanical ab initio calculations of the Raman scattering from psoralens. J Phys Condens Matter 2006;18:8325-36. Available from: <http://www.stacks.iop.org/0953-8984/18/i=35/a=017?key=crossref.7a39631f55a558529eb9a2b0f6680af9>.
- Devipriya B, Kumaradhas P. Charge density distribution and the electrostatic moments of CTPB in the active site of p300 enzyme: A DFT and charge density study. J Theor Biol 2013;335:119-29.
- Pires R, Marinho MM, Sá RA, Martins JL, Teixeira EH, Chagas F, et al. Compositional analysis of cashew (*Anacardium occidentale* L.) peduncle bagasse ash and its *in vitro* antifungal activity against *Fusarium* species. 2011;9:200-5.
- Brooijmans N, Kuntz ID. Molecular recognition and docking algorithms. Annu Rev Biophys Biomol Struct 2003;32:335-73. Available from: <http://www.annualreviews.org>.
- Sousa SF, Fernandes PA, Ramos MJ. Protein-ligand docking: Current status and future challenges. Proteins Struct Funct Bioinf 2006;65:15-26.
- Kitchen DB, Decornez H, Furr JR, Bajorath J. Docking and scoring in virtual screening for drug discovery: Methods and applications. Nat Rev Drug Discov 2004;3:935-49.
- Sooderhjelms SG, Ryde U. Protein-ligand interactions. In: Gohlke H, editor. Wiley-VCH Verlag GmbH and Co.; 2012. p. 121-44.
- Zanatta G, Barroso-Neto IL, Junior VB. Quantum biochemistry description of the human dopamine D3 receptor in complex with the selective antagonist eticlopride. J Proteomics Bioinform 2012;5:155-62. Available from: <https://www.omicsonline.org/quantum-biochemistry-description-of-the-human-dopamine-d3-receptor-in-complex-with-the-selective-antagonist-eticlopride-jpb.1000229.php?aid=7520>.
- Da Costa RF, Freire VN, Bezerra EM, Cavada BS, Caetano EW, De Lima Filho JL, et al. Explaining statin inhibition effectiveness of HMG-CoA reductase by quantum biochemistry computations. Phys Chem Phys 2012;14:1389-98.
- Zhang DW, Zhang JZ. Molecular fractionation with conjugate caps for full quantum mechanical calculation of protein-molecule interaction energy. J Chem Phys 2003;119:3599-605.

45. Devipriya B, Kumaradhas P. Probing the effect of intermolecular interaction and understanding the electrostatic moments of anacardic acid in the active site of p300 enzyme via DFT and charge density analysis. *J Mol Graph Model* 2012;34:57-66.
46. Da Silva JG, Souza IA, Higino JS, Siqueira JP, Pereira JV, Pereira MD. Atividade antimicrobiana do extrato de *Anacardium occidentale* Linn. em amostras multiresistentes de *Staphylococcus aureus*. *Braz J Pharmacogn* 2007;17:572-7.
47. Irwin JJ, Sterling T, Mysinger MM, Bolstad ES, Coleman RG. ZINC: A free tool to discover chemistry for biology. *J Chem Inf Model* 2012;52:1757-68.
48. Trott O, Olson A. NIH public access. *J Comput Chem* 2010;31:455-61.
49. Pavão F, Castilho MS, Pupo MT, Dias RL, Correa AG, Fernandes JB, et al. Structure of *Trypanosoma cruzi* glycosomal glyceraldehyde-3-phosphate dehydrogenase complexed with chalepin, a natural product inhibitor, at 1.95 Å resolution. *FEBS Lett* 2002;520:13-7.
50. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF chimera a visualization system for exploratory research and analysis. *J Comput Chem* 2004;25:1605-12.
51. Barroso-Neto IL, Marques JP, Da Costa RF, Caetano EW, Cavada BS, Gottfried C, et al. Inactivation of ovine cyclooxygenase-1 by bromoaspirin and aspirin: A quantum chemistry description. *J Phys Chem B* 2012;116:3270-9.
52. Momany FA, Rone R. Validation of the general purpose QUANTA®3.2/CHARMm® force field. *J Comput Chem* 1992;13:888-900.
53. Delley B. An all-electron numerical method for solving the local density functional for polyatomic molecules. *J Chem Phys* 1990;92:508-17.
54. Delley B. From molecules to solids with the DMol3 approach. *J Chem Phys* 2000;113:7756-64.
55. Inada Y, Orita H. Efficiency of numerical basis sets for predicting the binding energies of hydrogen bonded complexes: Evidence of small basis set superposition error compared to gaussian basis sets. *J Comput Chem* 2008;29:225-32.
56. Reed AE, Weinhold F. Natural localized molecular orbitals. *J Chem Phys* 1985;83:1736-40.
57. Politzer P, Murray JS. The fundamental nature and role of the electrostatic potential in atoms and molecules. *Theor Chem Acc* 2002;108:134-42.
58. Yearley EJ, Zhurova EA, Zhurov VV, Pinkerton AA. Experimental electron density studies of non-steroidal synthetic estrogens: Diethylstilbestrol and dienestrol. *J Mol Struct* 2008;890:240-8.
59. Hibbs DE, Overgaard J, Platts JA, Waller MP, Hursthouse MB. Experimental and theoretical charge density studies of tetrafluorophthalonitrile and tetrafluoroisophthalonitrile. *J Phys Chem B* 2004;108:3663-72.
60. Politzer P, Murray JS, Peralta-Inga Z. Molecular surface electrostatic potentials in relation to noncovalent interactions in biological systems. *Int J Quantum Chem* 2001;684:676-84.
61. Ophardt CE. Virtual ChemBook. Elmhurst College; 2003. Available from: <http://www.chemistry.elmhurst.edu/vchembook/index.html>. [Last accessed on 2018 Jan 25].
62. Prabavathi N, Nilufer A, Krishnakumar V. Vibrational spectroscopic (FT-IR and FT-Raman) studies, natural bond orbital analysis and molecular electrostatic potential surface of isoxanthopterin. *Spectrochim Acta Part A Mol Biomol Spectrosc* 2013;114:101-13.
63. Herring GE, Petrucci RH, Harwood WS, Madura J. General Chemistry: Principles and Modern Applications. 9th ed. New Jersey: Pearson Education Inc.; 2007.
64. Seminario J, editor. Recent Developments and Applications of Modern Density Functional Theory. 1st ed. Amsterdam, The Netherlands: Elsevier; 1996. p. 3-838. Available from: <https://www.sciencedirect.com/bookseries/theoretical-and-computational-chemistry/vol/4>.